A Level Playing Field? Medicare Tries To Balance Transparency, Confidentiality With Drug Price Negotiations
Executive Summary
Drug manufacturers may want more ability to communicate about their drug price negotiation experience with Medicare than CMS is proposing, but if that jeopardizes protections for proprietary information, it may not be worthwhile.
You may also be interested in...
Medicare Negotiation Final Guidance: No More ‘Gag’ Rules, But Other Changes Fall Short Of Hopes
CMS sends a warning to Medicare Part D plans that beneficiaries should have ‘meaningful’ formulary access to drugs with negotiated prices. However, the guidance does not broaden potential exclusions from negotiation for orphan drugs, to the disappointment of stakeholders.
Medicare Negotiation And The Politics Of Drug Pricing
Medicare pricing decisions will become ‘highly politicized,’ Scott Gottlieb predicts. The former FDA commissioner and CMS official also believes the program should rely on outside health technology assessment groups, and he offers his opinions on how negotiation will (or won’t) change patent litigation.